MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.
The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology.
The company was founded in 2000 and is headquartered in Rockville, Maryland.
Funding Rounds (2) - $57.02MUpdate
Current Team (10)Update
|Jul 14, 2016||PRNewswire UK All - Multiple Sclerosis Pipeline Review Report of 178 Companies|
|Jun 14, 2016||PRNewswire UK All - Global Therapeutic Antibody Bundle Report 2016 - Focus on ADCs, Bispecifics, Biosimilars & Biosuperiors Featuring 271 Therapeutics Companies - Research and Markets|
|Jun 8, 2016||PRNewswire UK All - Fc Protein and Glycoengineered Antibodies Market 2016-2021 & 2026 - The Concept of Engineered Antibodies Is Being Widely Used for Development for Biobetters/Biosimilars - Research and Markets|
|May 23, 2016||Med City News - Morning Read: Nvidia tech to support machine learning could create smarter medical imaging|
|May 20, 2016||PRNewswire All - Next-Generation Biologics Market 2016-2026|
|May 20, 2016||PRNewswire UK All - Next-Generation Biologics Market 2016-2026|
|May 19, 2016||Boston Tech Flash - MacroGenics scores drug licensing deal worth up to $740 million|
|May 11, 2016||PRNewswire UK All - Next Generation Antibody Therapies Market Forecast 2016-2026|
1500 East Gude Drive
Rockville, MD 20850